Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry
| Autor: | A. Prior-Español, C. Sánchez-Piedra, J. Campos, F. J. Manero, C. Pérez-García, C. Bohórquez, N. Busquets-Pérez, J. M. Blanco-Madrigal, C. Díaz-Torne, F. Sánchez-Alonso, L. Mateo, S. Holgado-Pérez |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2045-2322 67451470 |
| DOI: | 10.1038/s41598-021-90442-w |
| Popis: | Abstract Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The objective of the study was to identify factors associated with discontinuation of ts/bDMARDs in a real-world dataset. The study population comprised patients diagnosed with RA, PsA, and AS included in the BIOBADASER registry for whom follow-up data were available until November 2019. Patient features and treatment data were included in the analysis. The Kaplan–Meier method was used to study survival of the different drugs according to the reason for discontinuation. Factors associated with discontinuation were studied using Cox regression models and bivariate and multivariate analyses. P values of less than 0.05 were regarded as statistically significant. The study population comprised 4,752 patients who received a total of 8,377 drugs, of which 4,411 (52.65%) were discontinued. The Kaplan–Meier curves showed that survival for first-line treatment was greater in all 3 groups (p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|